Chaudhuri et al., 2006 - Google Patents
Glioma therapy: a novel insight in the immunotherapeutic regime with T11TS/SLFA-3Chaudhuri et al., 2006
View PDF- Document ID
- 13395985048412767210
- Author
- Chaudhuri S
- Ghosh A
- Publication year
- Publication venue
- Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents)
External Links
Snippet
Brain tumors of glial origin ie glioma are most difficult neoplasm to treat with modern therapeutic interventions viz. surgery, radio-and chemotherapies. Therefore, a continuous search is 'on'for the alternative modalities of treatment particularly with different …
- 206010018338 Glioma 0 title abstract description 193
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101399591B1 (en) | Concurrent chemotherapy and immunotherapy | |
| AU2001267780B2 (en) | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells | |
| US8828403B2 (en) | Anti-tumor immunotherapy | |
| US5820872A (en) | Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor | |
| CA2606871C (en) | Use of native peptides and their optimized derivatives for vaccination | |
| EP2234642B1 (en) | Method of increasing immunological effect | |
| JP2017155059A (en) | Vaccine immunotherapy | |
| Schneble et al. | Peptide-based cancer vaccine strategies and clinical results | |
| JP2021530444A (en) | Targeting multiple antigens on multiple CAR T cells in solid and liquid malignancies | |
| Graf et al. | Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination | |
| EP3129045B1 (en) | Method of treating melanoma | |
| Chaudhuri et al. | Glioma therapy: a novel insight in the immunotherapeutic regime with T11TS/SLFA-3 | |
| WO1999057981A1 (en) | Compositions and methods for active vaccination | |
| US20150307614A1 (en) | Enhanced immunological responses | |
| Kruse et al. | Cytotoxic T-lymphocytes reactive to patient major histocompatibility complex proteins for therapy of brain tumors | |
| Durrant et al. | Cancer vaccines entering Phase III clinical trials | |
| KR101224466B1 (en) | Tumor antigen protein, gene, or peptides from topoisomerase 2 alpha | |
| JP2001508764A (en) | Immunogenic TLP composition | |
| BR112019011262A2 (en) | pharmaceutical composition, methods for inducing or promoting t-cell activation, for inducing or promoting an immune response, for treating cancer and for treating an infection. | |
| Mahaley et al. | Immunotherapy of patients with glioma: fact, fancy, and future | |
| US20110135637A1 (en) | Trimodal cancer therapy | |
| Knight et al. | The HLA‐A2‐restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer | |
| Durham et al. | Dendritic cell vaccines: sipuleucel-T and other approaches | |
| Slovin | Cancer Immunotherapeutics Meeting | |
| Generoso | Six-transmembrane epithelial antigen of the postate (STREAP): a potential target of immunotherapy of prostate cancer. |